CML Clinical Trials
Cancer research is an area where new treatments are being explored for the prevention, diagnosis and treatment of different types of cancer. Researchers conduct so called “clinical studies” or “clinical trials” to improve treatment options for the patients of today and tomorrow. These studies are performed to investigate the biological mechanisms of the disease, to optimize the use of existing therapies or to test new forms of treatment or new drugs to find out whether they are more effective or better tolerated. For more information please read our manual “what are clinical trials?”
Patients wishing to participate in clinical studies often look for a central source of information where they can find easy-to-understand facts on ongoing trials. CML Advocates Network is now hosting an inofficial database of current CML trials which have been initiated by academia (universities) or by pharmaceutical companies.
This database is run by patients for patients and is set up as a dynamic register in which data are updated on an ongoing basis.
CML Advocates Network has taken utmost care to verify the data entered, however, cannot assume any liability for the accuracy or completeness of the information. Patients should consult their doctor for personal advice and/or their scientific contact/study staff for the most up-to-date study information.
Do you know of any study that is not yet listed here? Please let us know by filling out this form. Or is there an entry which should be corrected? If so, please send us an email. Please also visit our forum if you have any questions or wish to share your experience on these studies.
1. First line trials
2. Trials after therapy failure or intolerance
3. Therapy optimization trials
4. Treatment of advanced phases
5. Treatment discontinuation trials
6. Pediatric trials
7. Other trials
9. Trials that are no longer recruiting
1 DACOTA = Decitabine with or without Hydroxyurea versus Hydroxyurea in CMML[Europe]
2 FAsciNation = Frontline Asciminib Combination in Chronic Phase CML (CML XI) [Germany]
4 Matchpoint – Ponatinib and Intensive Chemotherapy [UK]
7 CALLS = CML and ALL Low Level Mutation Study in the UK [UK]
6 DASFREE (CA180-406) = Discontinuation of dasatinib in CP-CML patients with stable MR4.5
8 RERISE China = Radotinib versus Imatinib [China]
9 ASC4MORE (CABL001E2201) = A Phase II Study of ABL001 in Patients With CML-CP without Deep Molecular Response [Asia, Australia, Europe, North America, South America]
10 TRAD = Treatment-free Remission Accomplished With Dasatinib in Patients With CML [Canada]
11 ENDURE = Efficacy and Safety of AOP2014 With CML Patients in Remission [France, Germany]
12 Prospective Registry of Ponatinib in Belgium [Belgium]
13 DasaHIT = Dasatinib Holiday for Improved Tolerability [Germany]
15 Low Dose Dasatinib as First-Line Treatment [Middle East]
17 DasaHIT = Dasatinib Holiday for Improved Tolerability [Germany]
18 ENESTPath Patient’s Voice Italian Substudy [Italy]
19 CA180-226 = Dasatinib Powder for Oral Suspension Substudy [Mexico, Romania, Spain, USA]
20 OPUS = Optimizing Ponatinib Use [Italy]
21 QMH-CML-001 = Cessation of TKI in CML [Hong Kong]
22 BOSTRO = CML Treated With Bosutinib After Relapse [Spain]
23 OMNI = Registry to evaluate vascular occlusive events with Iclusig [US]
25 SUSTRENIM = Sustained Treatment-free Remission in Chronic Myeloid Leukemia [Belgium, Italy, Netherlands]
26 DASPERSE = Dasatinib in chronic phase myeloid leukemia patients with chronic toxicity to imatinib
30 DasaHIT = Dasatinib Holiday for Improved Tolerability [Germany]
31 BEST – Bosutinib in Elderly Chronic Myeloid Leukemia [Italy]
33 PIO2STOP = Second STOP After Pioglitazone Priming in CML Patients [France]
34 MSIT = Malaysia Stop Tyrosine Kinase Inhibitor Trial [Malaysia]
35 DECLINE (CAMN107ADE18T) = Imatinib versus nilotinib in CML in chronic phase [Germany]
36 CA180-357 = Decitabine + Dasatinib for Blast Phase CML
41 TIGER (CML V) = Nilotinib or nilotinib + peginterferon with the aim to discontinue treatment
42 Ruxolitinib for CML with minimal residual disease [USA]
46 LAST Stopping Tyrosine kinase inhibitors
48 CML-Paed II = Registration of Children with CML and Treatment with Imatinib [Germany]
49 EUROSKI (EUROStopKinaseInhibitor)
53 Eltrombopag for thrombocytopenia in CML
54 DASCERN (CA180-399) = Phase IIb Study of Dasatinib versus Imatinib (Early Switch)
55 BYOND (B1871039) = Safety and Efficacy of Bosutinib in Ph+ CML Previously Treated with TKI
56 CA180-373 = A Phase 1B Study with Dasatinib plus Nivolumab in CML
57 LEONIDAS = Quality-of-Life effects of imatinib and dasatinib in CML